For patients with active lupus nephritis, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody plus standard ...

In a new study, researchers investigated microRNA-203 as a potential biomarker for lupus nephritis (LN) and found that ...

March is here, and as we observe Kidney Month, it’s crucial to raise awareness about how lupus can severely impact the ...

Adding obinutuzumab to standard therapy for active lupus nephritis led to significantly higher rates of complete renal ...

The following is a summary of “Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis,” published in the February 2025 ...

Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner ...

WEDNESDAY, Feb. 26, 2025 (HealthDay News) -- For patients with active lupus nephritis, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody plus standard therapy is more efficacious for ...

More patients receiving obinutuzumab plus standard therapy versus standard therapy alone had a complete renal response at week 76. HealthDay News — For patients with active lupus nephritis, ...

The CHMP recommends granting a marketing authorization to NVS' Fabhalta for the treatment of adults with C3 glomerulopathy, an ultra-rare, progressive kidney disease with no currently approved ...